Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PTI 188

Next Previous
X
Search
Drug Profile

PTI 188

Alternative Names: 188Re-PTI-6D2; Anti-melanin monoclonal antibody; PTI-188; PTI-6D2

Latest Information Update: 01 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Albert Einstein College of Medicine
  • Developer Cassava Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 27 Mar 2019 Pain Therapeutics is now called Cassava Sciences
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma (Inoperable/Unresectable; Metastatic disease, Late stage disease, Second line therapy or greater) in Israel (IV, Infusion)
  • 02 Nov 2010 Pain Therapeutics receives a grant under the US Government's Qualifying Therapeutic Discovery Project Programme to support its research in oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top